Technology ID
TAB-4561

SARS-CoV-2 Neutralizing Nanobodies for Therapeutic and Diagnostic Uses

E-Numbers
E-244-2020-0
Lead Inventor
Casellas, Rafael (NIAMS)
Co-Inventors
Xu, Jianliang (NIAMS)
Applications
Research Materials
Therapeutic Areas
Infectious Disease
Development Stages
Pre-clinical (in vivo)
Research Products
Animal Models
Lead IC
NIAMS
ICs
NIAMS

This technology involves the utilization of highly effective nanobodies, specifically camelid antibodies, derived from immunized llamas to neutralize SARS-CoV-2. Additionally, it employs a unique mouse model, called a "nanomouse," that is engineered to express antibody genes from camels, alpacas, and dromedaries. These nanobodies offer significant advantages over traditional human and mouse antibodies due to their smaller size, which allows them to effectively target and bind to specific areas on antigens. The primary applications of this technology are twofold: therapeutically, to inhibit COVID-19 in patients, and diagnostically, to detect the presence of the infection in blood samples using methods like ELISA. This innovative approach holds promise for both treating and identifying COVID-19 more effectively.

Commercial Applications
Potential applications include blocking COVID-19 in patients and detecting the virus in blood samples, using methods such as ELISA or similar diagnostic techniques.

Competitive Advantages
The competitive advantage of this technology lies in its use of small, highly effective nanobodies from camelids, which can access antigen crevices that conventional human and mouse antibodies cannot, enhancing their potential for COVID-19 treatment and detection.

Request More Info

Licensing Contact:
Knezevic, Vladimir
vlado.knezevic@nih.gov

Publications

Collaborations

  • Materials Available

Collaboration Description

  • The research materials are available from the Jackson Laboratory (Strain # 036538).
Date Published